337 related articles for article (PubMed ID: 17249259)
1. Treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate.
Garg A; Duggal L; Aggarwal S; Jain N
J Assoc Physicians India; 2006 Nov; 54():883-6. PubMed ID: 17249259
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate: a case report.
Tan D; Hwang W; Ng HJ; Goh YT; Tan P
Int J Hematol; 2004 Jul; 80(1):75-7. PubMed ID: 15293573
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate treatment in two patients with idiopathic hypereosinophilic syndrome.
Payne SM; Kovacs MJ
Ann Pharmacother; 2004; 38(7-8):1215-8. PubMed ID: 15187212
[TBL] [Abstract][Full Text] [Related]
4. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
Cortes J; Kantarjian H
Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047
[TBL] [Abstract][Full Text] [Related]
5. Effective treatment of hypereosinophilic syndrome with imatinib mesylate.
Salem Z; Zalloua PA; Chehal A; Bitar N; Abboud M; Kadri A; Chami B; Bazarbachi A
Hematol J; 2003; 4(6):410-2. PubMed ID: 14671612
[TBL] [Abstract][Full Text] [Related]
6. [Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition].
Moles MP; Landry J; Roche-Lestienne C; Godon A; Schmidt-Tanguy A; Gardembas M; Le Clech C; Verret JL; Zandecki M; Blanchet O
Ann Biol Clin (Paris); 2005; 63(3):317-22. PubMed ID: 15951264
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate for the treatment of hypereosinophilic syndromes.
Antoniu SA
Curr Opin Investig Drugs; 2006 Nov; 7(11):980-4. PubMed ID: 17117585
[TBL] [Abstract][Full Text] [Related]
8. Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature.
Tsimberidou AM; Medina J; Cortes J; Rios A; Bonnie G; Faderl S; Kantarjian H; Garcia-Manero G
Leuk Res; 2004 Jun; 28(6):657-60. PubMed ID: 15120945
[TBL] [Abstract][Full Text] [Related]
9. Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib.
Hofmann SC; Technau K; Müller AM; Lübbert M; Bruckner-Tuderman L
J Am Acad Dermatol; 2007 May; 56(5 Suppl):S68-72. PubMed ID: 17097375
[TBL] [Abstract][Full Text] [Related]
10. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate.
Schaller JL; Burkland GA
MedGenMed; 2001 Sep; 3(5):9. PubMed ID: 11698916
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome.
Cortes J; Ault P; Koller C; Thomas D; Ferrajoli A; Wierda W; Rios MB; Letvak L; Kaled ES; Kantarjian H
Blood; 2003 Jun; 101(12):4714-6. PubMed ID: 12595304
[TBL] [Abstract][Full Text] [Related]
12. Hypereosinophilic syndrome: diagnosis and treatment.
Peros-Golubicić T; Smojver-Jezek S
Curr Opin Pulm Med; 2007 Sep; 13(5):422-7. PubMed ID: 17940488
[TBL] [Abstract][Full Text] [Related]
13. The hypereosinophilic syndromes: still more heterogeneity.
Gleich GJ; Leiferman KM
Curr Opin Immunol; 2005 Dec; 17(6):679-84. PubMed ID: 16214314
[TBL] [Abstract][Full Text] [Related]
14. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
Cools J; DeAngelo DJ; Gotlib J; Stover EH; Legare RD; Cortes J; Kutok J; Clark J; Galinsky I; Griffin JD; Cross NC; Tefferi A; Malone J; Alam R; Schrier SL; Schmid J; Rose M; Vandenberghe P; Verhoef G; Boogaerts M; Wlodarska I; Kantarjian H; Marynen P; Coutre SE; Stone R; Gilliland DG
N Engl J Med; 2003 Mar; 348(13):1201-14. PubMed ID: 12660384
[TBL] [Abstract][Full Text] [Related]
15. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of response to imatinib-mesylate (glivec) in patients with hypereosinophilic syndrome: implications for dosing and pathogenesis.
Musto P; Falcone A; Sanpaolo G; Bodenizza C; Perla G; Minervini MM; Cascavilla N; Dell'Olio M; La Sala A; Mantuano S; Melillo L; Nobile M; Scalzulli PR; Bisceglia M; Carella AM
Leuk Lymphoma; 2004 Jun; 45(6):1219-22. PubMed ID: 15360005
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of idiopathic hypereosinophilic syndrome with imatinib].
Sørensen AL; Larsen H
Ugeskr Laeger; 2008 Jan; 170(4):254. PubMed ID: 18282461
[TBL] [Abstract][Full Text] [Related]
18. Imatinib and hyperlipidemia.
Gottardi M; Manzato E; Gherlinzoni F
N Engl J Med; 2005 Dec; 353(25):2722-3. PubMed ID: 16371644
[No Abstract] [Full Text] [Related]
19. Platelet-derived growth factor receptor inhibition to treat idiopathic hypereosinophilic syndrome.
Stone RM; Gilliland DG; Klion AD
Semin Oncol; 2004 Apr; 31(2 Suppl 6):12-7. PubMed ID: 15175999
[TBL] [Abstract][Full Text] [Related]
20. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate.
Ault P; Cortes J; Koller C; Kaled ES; Kantarjian H
Leuk Res; 2002 Sep; 26(9):881-4. PubMed ID: 12127565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
